Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376435
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-11
Brief Title:
A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in ConcurrentSequential Radioimmunoinduced Thrombocytopenia
Sponsor:
Hebei Medical University Fourth Hospital
Organization:
Hebei Medical University Fourth Hospital
Study Overview
Official Title:
A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in ConcurrentSequential Radioimmunoinduced Thrombocytopenia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study was to observe and evaluate the efficacy and safety of hexapopal ethanolamine tablets in the treatment of synchronoussequential radioimmunoinduced thrombocytopenia in the real world
The subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia
This study will retrospectively and prospectively collect real-world data related to investigational drugs and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia The study included a screening period no more than one week and a treatment period at least two cyclesParticipants meeting protocol inclusion criteria were defined as having platelet values 100109L during radioimmunotherapy
The subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia
This study will retrospectively and prospectively collect real-world data related to investigational drugs and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia The study included a screening period no more than one week and a treatment period at least two cyclesParticipants meeting protocol inclusion criteria were defined as having platelet values 100109L during radioimmunotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None